Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
KEYNOTE-564研究中患者报告结局:帕博利珠单抗辅助治疗与安慰剂治疗肾细胞癌的比较
期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyad231
Choueiri, Toni K; Tomczak, Piotr; Park, Se Hoon; Venugopal, Balaji; Symeonides, Stefan; Hajek, Jaroslav; Ferguson, Thomas; Chang, Yen-Hwa; Lee, Jae Lyun; Haas, Naomi; Sawrycki, Piotr; Sarwar, Naveed; Gross-Goupil, Marine; Thiery-Vuillemin, Antoine; Mahave, Mauricio; Kimura, Go; Perini, Rodolfo F; Saretsky, Todd L; Bhattacharya, Rituparna; Xu, Lei; Powles, Thomas